LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Search

Quidel Corp

Fechado

10.75 -2.18

Visão Geral

Variação de preço das ações

24h

Atual

Mín

10.46

Máximo

11.51

Indicadores-chave

By Trading Economics

Rendimento

602M

-131M

Vendas

24M

724M

Margem de lucro

-18.062

Funcionários

6,500

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+29.29% upside

Dividendos

By Dow Jones

Próximos Ganhos

4 de ago. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-509M

700M

Abertura anterior

12.93

Fecho anterior

10.75

Quidel Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

7 de mai. de 2026, 23:58 UTC

Ganhos

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7 de mai. de 2026, 22:57 UTC

Ganhos

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7 de mai. de 2026, 23:52 UTC

Ganhos

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7 de mai. de 2026, 23:45 UTC

Conversa de Mercado

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7 de mai. de 2026, 23:39 UTC

Conversa de Mercado

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7 de mai. de 2026, 23:28 UTC

Conversa de Mercado

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7 de mai. de 2026, 23:11 UTC

Ganhos

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7 de mai. de 2026, 23:06 UTC

Ganhos

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7 de mai. de 2026, 23:05 UTC

Ganhos

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7 de mai. de 2026, 23:04 UTC

Ganhos

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7 de mai. de 2026, 23:03 UTC

Ganhos

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7 de mai. de 2026, 23:03 UTC

Ganhos

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7 de mai. de 2026, 23:02 UTC

Ganhos

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7 de mai. de 2026, 23:00 UTC

Conversa de Mercado

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7 de mai. de 2026, 22:45 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 de mai. de 2026, 22:45 UTC

Conversa de Mercado

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7 de mai. de 2026, 22:42 UTC

Ganhos

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7 de mai. de 2026, 22:33 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 de mai. de 2026, 22:32 UTC

Ganhos

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7 de mai. de 2026, 22:31 UTC

Ganhos

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7 de mai. de 2026, 22:31 UTC

Ganhos

Macquarie: 68% of FY Income From International >MQG.AU

7 de mai. de 2026, 22:30 UTC

Ganhos

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7 de mai. de 2026, 22:30 UTC

Ganhos

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7 de mai. de 2026, 22:29 UTC

Ganhos

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7 de mai. de 2026, 22:28 UTC

Ganhos

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7 de mai. de 2026, 22:28 UTC

Ganhos

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7 de mai. de 2026, 22:27 UTC

Ganhos

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7 de mai. de 2026, 22:27 UTC

Ganhos

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7 de mai. de 2026, 22:26 UTC

Ganhos

Macquarie to End Share Buyback Extended in November>MQG.AU

7 de mai. de 2026, 22:25 UTC

Ganhos

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Comparação entre Pares

Variação de preço

Quidel Corp Previsão

Preço-alvo

By TipRanks

29.29% parte superior

Previsão para 12 meses

Média 14.17 USD  29.29%

Máximo 17 USD

Mínimo 11.66 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Quidel Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

5 ratings

1

Comprar

3

Manter

1

Vender

Informação Financeira

Custos administrativos e de venda

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

Resultado Operacional

$

Sobre Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat